Repeat pull from proven relationships plus room left: the installed base is expanding on its own initiative and is still
The model's full reasoning — Q2 2023 call → NO我们根据提供的财报电话会议记录来分析。管理层是否描述了现有客户、账户、合作伙伴、成员或项目已经主动采取或承诺更多行动（更大或更早的再订购、更广泛的部署、增加站点、产品或范围、关系升级到更大阶段），并且管理层是否传达了这些关系仍然渗透不足——到目前为止这些对手方所采取的行动仍然只是他们可能采取的一小部分——因此现在可见的扩张还为时尚早？ 我们需要在管理层的原话中寻找两个部分：1）实际扩张行为已经发生，且不只是个别账户，而是由对手方自身选择驱动的；2）管理层传达这些关系中仍有大量空间。 关键词：现有客户、扩张、渗透不足、早期。 在记录中，Brian和Johnny提到了多个方面。例如，关于PhenoCycler-Fusion的2.0升级，他们提到“field upgrades started with our first customers in June”，并期望“a significant percentage of our PhenoCycler-Fusion customers to upgrade by year-end”。这涉及现有客户升级，但这是产品升级，不一定意味着他们主动采取更多量，只是技术更新。 关于试剂收入增长，Johnny提到“annualized second quarter reagent pull-through has now increased to the mid-$30,000 range for both the PhenoCycler and HT”，而2022年是低$30,000。这表明每个仪器的试剂消耗增加，但这是综合表现，不一定明确是现有客户增加使用。 更直接的是关于CRO网络和生物制药合作伙伴。Brian提到“we continue to see robust growth in the translational markets with growing momentum within our biopharma and CRO partners”。还有关于Acrivon的合作，Johnny提到“the continued advancement of the Acrivon CDx”以及“both are both continuing to advance with kind of larger scale projects with our biopharma customers through our CLIA Lab”。 在回答问题时，Brian提到“on the HT... increasing utility of HT among biopharma and CROs”，并说“these are also our target customers for the recently launched PhenoCode signature panels”。他还提到“we are seeing encouraging results of our emphasis on driving reagent growth”。 然而，我们没有看到明确的描述说现有客户自己主动增加订单、扩大部署等。更多的是总体增长和产品发布。关于渗透不足，Brian提到“if you just look at our top 15 to 20 that are maybe fivefold above that mid-$30,000 range, they're all PCF customers”，这表明一些客户使用量很高，但整体中位数仍低。他还说“we do feel like that median is going to begin to shift to a larger and larger pull-through”，这暗示还有提升空间。 但关键是要找管理层明确说现有关系渗透不足，目前只是早期。在回答分析师问题时，Brian说“I think as we look at the market opportunity for us... we think there's huge opportunity”，但这是关于市场。 更具体的，关于CRO网络，Brian说“we are also making additional workflow improvements...
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PPC | Pilgrim's Pride Corporation | Q1 2024 | 2024-05-03 | A |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| FARM | Farmer Bros. Co. | Q3 2022 | 2022-05-07 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| DGX | Quest Diagnostics Incorporated | Q2 2021 | 2021-07-22 | B+ |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| CVS | CVS Health Corporation | Q1 2018 | 2018-05-02 | B+ |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
ZVIA · Q1 2022 → YESThe question is about whether management describes existing customers taking more from the company on their own initiative, and that these relationships are still lightly penetrated. YES Management describes existing customers (households and Club channel buyers) already taking meaningfully more through velocity (51% of growth), higher buy rates (+9%), and heavier consumption in the food channel, while conveying that these relationships remain lightly penetrated with substantial room ahead (new households, expanded flavors, broader deployments). This is 100% present-tense, driven by counterparties’ own choice after direct experience, not price hikes or auto-renewal, and the expansion is already occurring across multiple accounts rather than isolated or projected.
PI · Q4 2022 → YESThe question is about whether management describes existing customers expanding their business with the company, and that these relationships are still lightly penetrated. YES The transcript shows management describing existing customers expanding through program expansions, broader deployments, and continued system deployments that are already occurring and expected to drive large volumes in 2023 and beyond, while conveying that these relationships remain lightly penetrated with substantial room for further growth in scope, sites, and usage.
CVS · Q1 2018 → YESThe question is about whether management describes existing customers taking more from the company on their own initiative, and that these relationships are still lightly penetrated. YES The transcript shows management describing existing partnerships (Optum and Cigna clients) already taking more programs through an uptick in CVS Pharmacy and MinuteClinic offerings, driven by the companies' own adoption after experience, with continued opportunities for 2020 and beyond indicating substantial room remains in those relationships.